International Journal of Transgender Health
March 19, 2025
Skylar J. Gaughan, Angie R. Wootton, Daphne Krantz et al.
6 citations
Transgender and gender-expansive (TGE) people use psychedelics in naturalistic, non-clinical settings to explore and affirm their gender identity. Interviews with 20 TGE individuals revealed three main themes: the mindset and physical setting of a psychedelic experience shape its quality; such experiences often increase self-acceptance of gender identity through greater self-compassion and a broader concept of gender; and participants reported both challenging effects like gender dysphoria and benefits like gender euphoria. The findings suggest clinicians should help TGE clients prepare a gender-affirming setting before psychedelic use and support shifts in gender understanding afterward.
Science
September 19, 2024
Stacey B. Armstrong, Alan K. Davis
6 citations
Psychedelic-assisted therapy (PAT) combines hallucinogenic drugs like psilocybin and MDMA with psychotherapy, showing potential for treating mental health conditions that affect one in eight people worldwide. Clinical trials in the US and Europe suggest PAT may offer shorter treatment times and stronger effects than existing therapies. However, the field faces significant controversy due to unanswered questions about safety and effectiveness, highlighted by the FDA's recent decision against approving MDMA therapy for PTSD and the retraction of several MDMA trial papers due to unethical therapist conduct and data integrity issues. The research community must address these obstacles to transition from exploratory trials to established, evidence-based treatments.
Journal of Psychedelic Studies
August 5, 2022
John Clifton, Annabelle M. Belcher, Aaron D. Greenblatt et al.
6 citations
Among Black individuals diagnosed with Opioid Use Disorder recruited from an urban methadone program, most had heard of psilocybin mushrooms but only 17.8% had ever used them. Over 80% perceived a risk or were unsure of the risk for most psilocybin-related items. About half were willing to try therapy incorporating psilocybin, and half said they would be more likely to try it if FDA-approved for OUD. Most preferred to stay on methadone alone; only one participant chose psilocybin treatment without methadone. The authors suggest culturally informed treatment models and outreach to increase minority representation in psilocybin research.
Journal of Humanistic Psychology
February 27, 2024
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
5 citations
People who attended an ayahuasca retreat showed increased appreciation of art and beauty one week and one month later, according to a survey of 54 participants. Contrary to expectations, intense drug effects such as mystical experiences, awe, or ego dissolution did not predict these changes. The open-label design limits certainty, but the findings align with anecdotal reports of lasting shifts in aesthetic attitudes after psychedelic use. Further research is needed to identify the mechanisms behind these changes.
Journal of Psychedelic Studies
September 4, 2025
Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda et al.
4 citations
Over a five-year follow-up period, psilocybin-assisted therapy produced significant and sustained reductions in depression for people with major depressive disorder. Among the 18 participants who completed the study, 67% remained in remission for at least five years after treatment. Anxiety and functional impairment also improved. Qualitative interviews revealed lasting positive changes in mindset, emotional health, and relationships, including enhanced empathy, self-acceptance, and improved interpersonal relationships. No severe adverse events were reported. These findings support the long-term efficacy and safety of psilocybin-assisted therapy for reducing depressive symptoms and improving mental health.
Journal of Psychoactive Drugs
September 12, 2024
Katinka Hooyer, Rachel Yehuda, Alan K. Davis et al.
4 citations
About half of U.S. military veterans surveyed reported using psychedelics, most often for healing or treatment (70%) and spiritual purposes (48%). The vast majority (85%) said they benefited from use. Veterans who used psychedelics indicated they would be more likely to use VA services, and they expressed greater interest in psychedelic therapy compared to non-users. However, some adverse outcomes were reported, suggesting that without proper preparation and support, psychedelics may carry risks. The findings point to a potential role for psychedelic-assisted approaches in veteran mental health care.
Journal of Psychedelic Studies
June 5, 2024
Meghan DellaCrosse, A. Garcia-Romeu, Alan K. Davis
4 citations
A lack of consensus and theoretical clarity in psychedelic-assisted therapy research has led to polarized debates and unusual regulatory recommendations, such as removing psychological and medical safety measures to better study drug effects. This commentary argues that an ecological systems theory approach, adapted from Bronfenbrenner, can make contextual and practical factors explicit and testable in research. The proposed conceptual model aims to improve measurement of acute subjective experience and address limitations in current approaches. The authors suggest this framework could help reconcile conflicting perspectives and enhance safety in ongoing clinical trials.
Journal of Psychoactive Drugs
July 14, 2023
Christopher Timmermann, Aki Nikolaidis, Alan K. Davis et al.
4 citations
Spanish translations of three questionnaires measuring acute psychedelic effects—the Psychological Insight Questionnaire (PIQ), Challenging Experiences Questionnaire (CEQ), and Mystical Experiences Questionnaire (MEQ)—showed good psychometric properties in a sample of 442 native Spanish speakers. Confirmatory factor analysis confirmed that the factor structures matched the original English versions, and this consistency held across subgroups who had used LSD or psilocybin. Construct validity was supported by positive associations between the PIQ and MEQ and between these measures and changes in cognitive fusion, alongside negative associations with changes in prosocial behaviors. Predictive validity was indicated by strong relationships between persisting effects and scores on the MEQ and PIQ. The Spanish versions can be reliably used in research with Spanish-speaking populations.
May 15, 2023
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
3 citations
preprint
People who attended an ayahuasca retreat showed increased engagement with aesthetic experiences—such as appreciation of art, nature, and beauty—one week and one month afterward, compared to before the retreat. The study followed 54 participants and measured aesthetic experience using a validated questionnaire. Although participants reported strong mystical-type experiences, awe, and ego dissolution during their ayahuasca sessions, none of these acute effects predicted the long-term increase in aesthetic engagement. The open-label design limits certainty, but the findings support anecdotal reports that psychedelics can enhance aesthetic appreciation and point to a new area for future research.
JAMA Psychiatry
February 10, 2021
Alan K. Davis, Roland R. Griffiths
3 citations
No Summary
June 7, 2023
Jacob S. Aday, Emily K. Bloesch, Alan K. Davis et al.
1 citation
preprint
People who attended an ayahuasca retreat showed increased gratitude, nature relatedness, and nature appreciation one week and one month afterward, compared with before the retreat. Mystical-type experiences and feelings of awe during the retreat were weakly to moderately linked to these increases, while ego dissolution was not. The findings suggest that the mystical and awe-inducing aspects of ayahuasca may lead to personality changes that benefit mental health and prosocial attitudes, though more research is needed to confirm the results.
Psychedelic Medicine
May 9, 2026
Yitong Xin, Alan K. Davis, Susan Yoon et al.
People with higher psychological resilience before an ayahuasca retreat reported more intense acute challenging experiences, such as nausea or emotional distress. Resilience also moderated how those challenging experiences related to later meaning-making: among participants with higher baseline resilience, the link between acute difficulty and a subsequent search for meaning in life was stronger. The findings suggest that resilience may help individuals transform difficult psychedelic moments into psychospiritual growth, pointing to the value of incorporating resilience-building into retreat preparation and integration programs.
January 8, 2026
Michael Esposito, Ana M Ortiz Bernal, Alan K. Davis et al.
preprint
A scoping review of 33 peer-reviewed studies on 5-MeO-DMT use in humans found that most interventional studies (13 of 15) used inhalation administration, though dosages and dosing regimens varied widely. Common outcomes measured include cognition, depression, post-traumatic stress disorder, and anxiety. The review highlights large heterogeneity in study design, dosing, and support, and suggests future research should explore different routes of administration and include more neuroimaging, qualitative, and longitudinal data.
Psychedelics
November 15, 2025
Meghan DellaCrosse, Shoval Gilead, Rafael Lancelotta et al.
Spanish-speaking individuals who had a memorable psilocybin or LSD experience reported two main themes: deep connection (to nature, others, the present moment, and the substance) and emotion-related experiences (from joy and peace to emotional processing, catharsis, and challenging experiences). The findings are based on a secondary qualitative analysis of open-ended survey responses from 379 Spanish-speaking participants. Similarities appeared across both substances, with some unique nuances. The work underscores the need for diverse populations in psychedelic research to improve generalizability and cultural relevance, and highlights the therapeutic potential of psychedelics while calling for culturally sensitive tools.
November 4, 2024
Jacob S. Aday, Jenna McAfee, Deirdre A. Conroy et al.
preprint
In a small open-label proof-of-concept trial, five adults with fibromyalgia received two doses of psilocybin (15 mg and 25 mg) two weeks apart, along with psychotherapy sessions. No serious adverse events occurred; transient blood pressure or heart rate elevations during dosing resolved by the end of treatment, and four of five participants had temporary headaches. One month after the second dose, participants reported clinically meaningful improvements in pain severity, pain interference, and sleep disturbance. One participant rated their symptoms as very much improved, two as much improved, and two as minimally improved. Improvements were also seen in fibromyalgia symptoms, anxiety, and fatigue. The findings suggest psilocybin-assisted therapy is well-tolerated and warrants larger randomized controlled trials.
Journal of Psychedelic Studies
September 17, 2024
Adam W. Levin, Aryan Sarparast, Paul B Nagib et al.
Among a sample of 180 American psychiatrists (mean age 48.4, 65.5% male, 24.1% trainees), about one-third (32.8%) reported personal use of and social connection to psychedelics. Psychiatrists with such personal connection tended to be younger and have fewer years of practice. Those with personal and social connection were more likely to disagree that using illegal drugs is morally wrong, that users should go to prison, are weak-minded, have no future, are poorly educated, are dishonest, or make them angry. Personal and social proximity to psychedelics is associated with less stigma toward drug use and people who use drugs.
Drug and Alcohol Dependence
July 1, 2024
Alan K. Davis, Adam W. Levin, Rafael Lancelotta et al.
No Summary
August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
A living systematic review and individual patient data meta-analysis is planned to assess the efficacy and safety of psilocybin for major depressive disorder (MDD). The review will include randomized and non-randomized trials, searching major databases and trial registries, and will analyze primary outcomes of depression severity using validated scales, with secondary outcomes including anxiety, hopelessness, quality of life, and death acceptance. Hierarchical mixed-effects models will account for clustering across studies and examine moderators like age, sex, baseline severity, prior psilocybin use, and dose. The review will be updated continuously as new evidence emerges to inform clinical practice and policy.